Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplinesincluding chemistry, engineering, physics, molecular biology, neurosciences and imaging sciencesto promote the emerging field of molecular neuroimaging.
"Molecular Imaging Symposium: Envisioning the Future of Neuroscience," which is taking place May 6-7 at the Natcher Auditorium of the National Institutes of Health (NIH) in Bethesda, Md., has attracted physicians and researchers from the basic science, translational and clinical communities, including a number of scientists-in-training. The meeting focuses on advances in targeted multimodality imaging of the central nervous system (CNS), including imaging of the bloodbrain barrier, tumors, neuroreceptors, stem cells, adoptive immunotherapies and other biological processes relevant to the CNS.
This morning, the meeting kicked off with a keynote speech by William Pardridge, M.D., from the University of California, Los Angeles. Partridge discussed the design and engineering of molecular "Trojan horses" as a way to smuggle biopharmaceuticals past the blood-brain barrier.
The keynote speech was followed by the first of four sessions for the day, each of which began with a lecture and concluded with a panel discussion and question and answer session. The first session provided an overview and introduction to molecular neuroimaging, going into detail about the molecular imaging techniques now in clinical use, including PET, SPECT, preclinical and intraoperative imaging.
"One of the main objectives of the meeting is to show the scientific and clinical communities the great potential behind targeted multimodality molecular neuroimaging," said Michelle S. Bradbury, Ph.D., M.D., of the Sloan-Kettering Institute for Cancer Research, New York, and co-chair of the program committee. "By wedding state-of-the-art imaging technologies with novel
|Contact: Amy Shaw|
Society of Nuclear Medicine